Overview

Gender

unknow

Wing-Kai’s roles have included Director, National Center of Excellence for Clinical Trial and Research at the National University Hospital, Taiwan, and Medical Director in Roche Asia/Pacific and in that capacity, participated in the clinical development of a number of anti-cancer drugs such as: Rituxan, Herceptin and Xeloda, to name a few. Wing-Kai is a medical graduate of the University of New South Wales, Sydney, Australia and a Fellow of the Royal Australian College of Physicians. He is also a member of American Society of Clinical Oncology. Wing-Kai has authored many publications in clinical oncology over the course of his distinguished career. Wing-Kai is based in Taipei, Taiwan and Hong Kong.